Cargando…

Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice

Detalles Bibliográficos
Autores principales:	Wang, Wenjun, Huang, Baoying, Zhu, Yanping, Tan, Wenjie, Zhu, Mingzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880661/ https://www.ncbi.nlm.nih.gov/pubmed/33580169 http://dx.doi.org/10.1038/s41423-021-00643-6

Ejemplares similares

In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine
por: Masoomi Nomandan, Seyedeh Zeinab, et al.
Publicado: (2022)

Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
por: Abayasingam, Arunasingam, et al.
Publicado: (2021)

Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
por: Tian, Siyu, et al.
Publicado: (2021)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
por: Sun, Shihui, et al.
Publicado: (2021)

Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2
por: Lin, Yifan, et al.
Publicado: (2022)

Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies
por: Liu, Bingfeng, et al.
Publicado: (2020)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages
por: Kalathiya, Umesh, et al.
Publicado: (2021)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
por: Wagner, Angelika, et al.
Publicado: (2021)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
por: Choi, Bina, et al.
Publicado: (2020)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge
por: Lee, Dan Bi, et al.
Publicado: (2023)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients
por: Deng, Yao, et al.
Publicado: (2021)

Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings
por: Ling, Zhoukun, et al.
Publicado: (2020)

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection
por: Reuken, Philipp A., et al.
Publicado: (2021)

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
por: Roarty, Cathal, et al.
Publicado: (2021)

The presence of SARS-CoV2 antibodies in MS patients
por: Wallach, Asya I., et al.
Publicado: (2021)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2
por: Gomes, Larissa R., et al.
Publicado: (2021)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections
por: Yang, Ren, et al.
Publicado: (2020)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19
por: Ceulemans, Laurens J, et al.
Publicado: (2021)

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
por: Haycroft, Ebene R., et al.
Publicado: (2023)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 in people living with HIV
por: Yamamoto, Shinya, et al.
Publicado: (2021)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Ghafari, Mahan, et al.
Publicado: (2021)

Prevalence of SARS-Cov-2 Antibodies in Emergency Medicine Healthcare Workers
por: Wang, Ralph C., et al.
Publicado: (2021)

Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l2o6gn8s6c5cudhu2jsg2eedcd